Ironwood Pharmaceuticals, Inc., an entrepreneurial pharmaceutical company, engages in developing and marketing human medicines. It engages in developing a pipeline of clinical candidates in the areas of gastrointestinal diseases, cardiovascular diseases, pain, and inflammation. The company's operationally independent subsidiary, Microbia Inc., engages in developing and commercializing bioprocesses for use in pharmaceuticals, foods, and specialty and industrial chemicals. Ironwood Pharmaceuticals, Inc. was formerly known as Microbia, Inc. The company was founded in 1998 and is headquartered in Cambridge, Massachusetts.

Research Grants 1 show all


$352.3K
2009

Patents 715show all

  • 246
    A61K - Preparations for medical, dental, or toilet purposes
  • 175
    C07D - Heterocyclic compounds
  • 88
    C07K - Peptides
  • 55
    Y02A - Technologies for adaptation to climate change
  • 27
    C07C - Acyclic or carbocyclic compounds
  • 24
    A61P - Specific therapeutic activity of chemical compounds or medicinal preparations
  • 22
    G01N - Investigating or analysing materials by determining their chemical or physical properties
  • 13
    C07F - Acyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium
  • 13
    C11D - Detergent compositions
  • 7
    B65D - Containers for storage or transport of articles or materials, e.g. bags, barrels, bottles, boxes, cans, cartons, crates, drums, jars, tanks, hoppers, forwarding containers

Clinical Trials 45show all

17Phase 214Phase 37Phase 44Phase 13N/A

SEC Filings show all


119
8-K

30
10-Q

11
10-K

6
D

1
S-1

Contact Information

301 Binney Street
Cambridge, MA 02142
United States

Overview

Total FundingEmployeesLast Funding DateStatus
$609,000,000501-10002016-09-26Ipo

Crunchbase Investment Rounds

DateAmountRoundValuationLead InvestorOther Investors
1999-01-01$10,000,000Series AVenrock
2004-05-01$50,000,000Series DGGV Capital, Venrock
2006-02-01$75,000,000Series EVenrock
2013-01-10$175,000,000Post Ipo Debt
2016-09-26$150,000,000Post Ipo Debt
2008-10-01$50,000,000Series G
2007-03-01$50,000,000Series FVenrock, Morgan Stanley
2002-04-01$26,000,000Series CVenrock
2000-11-01$23,000,000Series BVenrock

SEC Form D Funding Events

DateOfferedSoldType
2013-01-10$175,000,000$175,000,000Debt
2009-11-17$15,000,018$15,000,018Equity
2009-09-03$24,999,996$24,999,996Equity
2009-09-03$249,996$249,996Equity
2008-09-26Unknown Unknown Other (Paper Filing)

Key Executives

  • David Ebersman
    Director
  • Peter M. Hecht
    Executive Officer, Director
  • Michael J. Higgins
    Executive Officer
  • Joseph C. Cook, Jr.
    Director
  • Stephen Knight
    Director
  • Terrance G. Mcguire
    Director
  • Gina Bornino Miller
    Director
  • Bryan E. Roberts
    Director
  • Christopher T. Walsh
    Director
  • David Shaw
    Director
  • George H. Conrades
    Director
  • Mark G. Currie
    Executive Officer
  • Marsha Fanucci
    Director
  • Thomas Mccourt
    Executive Officer
  • David A. Ebersman
    Director
  • Marsha H. Fanucci
    Director
  • David E. Shaw
    Director